Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD

Y. Ogawa, M. Dogru, M. Uchino, Y. Tatematsu, M. Kamoi, Y. Yamamoto, J. Ogawa, R. Ishida, M. Kaido, S. Hara, Y. Matsumoto, T. Kawakita, Shinichiro Okamoto, Kazuo Tsubota

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Fibrosis and excessive extracellular matrix production are characteristic features of lacrimal gland chronic GVHD (cGVHD). Tranilast (n-3,4-anthoranilic acid), used for fibrotic skin disease, inhibits transforming growth factor-Β-induced matrix production. We conducted a non-randomized study comparing 8 patients (five men, three women; median age, 47 years) given topical tranilast with 10 patients (three men, seven women; median age, 37 years) receiving therapy with topical artificial tears, sodium hyaluronate and vitamin A for mild ocular cGVHD. The tranilast group instilled topical tranilast and artificial tears q.i.d., beginning the day of dry eye diagnosis. The ocular surface and tear dynamics of each patient were evaluated before hematopoietic stem cell transplant, at the onset of dry eye and after 3 months of treatment. At 3 months, the scores of the Rose Bengal test and Schirmer test with nasal stimulation had significantly improved in the tranilast group compared with that in the control group (P<0.05). Furthermore, although five control patients (50) developed severe dry eye within the treatment period, only one tranilast-treated patient (12.5) did; the rest still had mild dry eye (P<0.05). These results suggest the hypothesis that topical tranilast may effectively retard the progression of mild dry eye associated with cGVHD.

Original languageEnglish
Pages (from-to)565-569
Number of pages5
JournalBone Marrow Transplantation
Volume45
Issue number3
DOIs
Publication statusPublished - 2010

Fingerprint

Therapeutics
Rose Bengal
Lacrimal Apparatus
Transforming Growth Factors
Hyaluronic Acid
Hematopoietic Stem Cells
tranilast
Vitamin A
Tears
Nose
Skin Diseases
Extracellular Matrix
Fibrosis
Transplants
Control Groups
Acids
Lubricant Eye Drops

Keywords

  • Chronic GVHD
  • Dry eye
  • Fibrosis
  • Topical tranilast
  • Transforming growth factor-b

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. / Ogawa, Y.; Dogru, M.; Uchino, M.; Tatematsu, Y.; Kamoi, M.; Yamamoto, Y.; Ogawa, J.; Ishida, R.; Kaido, M.; Hara, S.; Matsumoto, Y.; Kawakita, T.; Okamoto, Shinichiro; Tsubota, Kazuo.

In: Bone Marrow Transplantation, Vol. 45, No. 3, 2010, p. 565-569.

Research output: Contribution to journalArticle

Ogawa, Y, Dogru, M, Uchino, M, Tatematsu, Y, Kamoi, M, Yamamoto, Y, Ogawa, J, Ishida, R, Kaido, M, Hara, S, Matsumoto, Y, Kawakita, T, Okamoto, S & Tsubota, K 2010, 'Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD', Bone Marrow Transplantation, vol. 45, no. 3, pp. 565-569. https://doi.org/10.1038/bmt.2009.173
Ogawa, Y. ; Dogru, M. ; Uchino, M. ; Tatematsu, Y. ; Kamoi, M. ; Yamamoto, Y. ; Ogawa, J. ; Ishida, R. ; Kaido, M. ; Hara, S. ; Matsumoto, Y. ; Kawakita, T. ; Okamoto, Shinichiro ; Tsubota, Kazuo. / Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. In: Bone Marrow Transplantation. 2010 ; Vol. 45, No. 3. pp. 565-569.
@article{cc9aa2e9b5924aedaaade213a0415566,
title = "Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD",
abstract = "Fibrosis and excessive extracellular matrix production are characteristic features of lacrimal gland chronic GVHD (cGVHD). Tranilast (n-3,4-anthoranilic acid), used for fibrotic skin disease, inhibits transforming growth factor-Β-induced matrix production. We conducted a non-randomized study comparing 8 patients (five men, three women; median age, 47 years) given topical tranilast with 10 patients (three men, seven women; median age, 37 years) receiving therapy with topical artificial tears, sodium hyaluronate and vitamin A for mild ocular cGVHD. The tranilast group instilled topical tranilast and artificial tears q.i.d., beginning the day of dry eye diagnosis. The ocular surface and tear dynamics of each patient were evaluated before hematopoietic stem cell transplant, at the onset of dry eye and after 3 months of treatment. At 3 months, the scores of the Rose Bengal test and Schirmer test with nasal stimulation had significantly improved in the tranilast group compared with that in the control group (P<0.05). Furthermore, although five control patients (50) developed severe dry eye within the treatment period, only one tranilast-treated patient (12.5) did; the rest still had mild dry eye (P<0.05). These results suggest the hypothesis that topical tranilast may effectively retard the progression of mild dry eye associated with cGVHD.",
keywords = "Chronic GVHD, Dry eye, Fibrosis, Topical tranilast, Transforming growth factor-b",
author = "Y. Ogawa and M. Dogru and M. Uchino and Y. Tatematsu and M. Kamoi and Y. Yamamoto and J. Ogawa and R. Ishida and M. Kaido and S. Hara and Y. Matsumoto and T. Kawakita and Shinichiro Okamoto and Kazuo Tsubota",
year = "2010",
doi = "10.1038/bmt.2009.173",
language = "English",
volume = "45",
pages = "565--569",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD

AU - Ogawa, Y.

AU - Dogru, M.

AU - Uchino, M.

AU - Tatematsu, Y.

AU - Kamoi, M.

AU - Yamamoto, Y.

AU - Ogawa, J.

AU - Ishida, R.

AU - Kaido, M.

AU - Hara, S.

AU - Matsumoto, Y.

AU - Kawakita, T.

AU - Okamoto, Shinichiro

AU - Tsubota, Kazuo

PY - 2010

Y1 - 2010

N2 - Fibrosis and excessive extracellular matrix production are characteristic features of lacrimal gland chronic GVHD (cGVHD). Tranilast (n-3,4-anthoranilic acid), used for fibrotic skin disease, inhibits transforming growth factor-Β-induced matrix production. We conducted a non-randomized study comparing 8 patients (five men, three women; median age, 47 years) given topical tranilast with 10 patients (three men, seven women; median age, 37 years) receiving therapy with topical artificial tears, sodium hyaluronate and vitamin A for mild ocular cGVHD. The tranilast group instilled topical tranilast and artificial tears q.i.d., beginning the day of dry eye diagnosis. The ocular surface and tear dynamics of each patient were evaluated before hematopoietic stem cell transplant, at the onset of dry eye and after 3 months of treatment. At 3 months, the scores of the Rose Bengal test and Schirmer test with nasal stimulation had significantly improved in the tranilast group compared with that in the control group (P<0.05). Furthermore, although five control patients (50) developed severe dry eye within the treatment period, only one tranilast-treated patient (12.5) did; the rest still had mild dry eye (P<0.05). These results suggest the hypothesis that topical tranilast may effectively retard the progression of mild dry eye associated with cGVHD.

AB - Fibrosis and excessive extracellular matrix production are characteristic features of lacrimal gland chronic GVHD (cGVHD). Tranilast (n-3,4-anthoranilic acid), used for fibrotic skin disease, inhibits transforming growth factor-Β-induced matrix production. We conducted a non-randomized study comparing 8 patients (five men, three women; median age, 47 years) given topical tranilast with 10 patients (three men, seven women; median age, 37 years) receiving therapy with topical artificial tears, sodium hyaluronate and vitamin A for mild ocular cGVHD. The tranilast group instilled topical tranilast and artificial tears q.i.d., beginning the day of dry eye diagnosis. The ocular surface and tear dynamics of each patient were evaluated before hematopoietic stem cell transplant, at the onset of dry eye and after 3 months of treatment. At 3 months, the scores of the Rose Bengal test and Schirmer test with nasal stimulation had significantly improved in the tranilast group compared with that in the control group (P<0.05). Furthermore, although five control patients (50) developed severe dry eye within the treatment period, only one tranilast-treated patient (12.5) did; the rest still had mild dry eye (P<0.05). These results suggest the hypothesis that topical tranilast may effectively retard the progression of mild dry eye associated with cGVHD.

KW - Chronic GVHD

KW - Dry eye

KW - Fibrosis

KW - Topical tranilast

KW - Transforming growth factor-b

UR - http://www.scopus.com/inward/record.url?scp=77949424089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949424089&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.173

DO - 10.1038/bmt.2009.173

M3 - Article

C2 - 19633693

AN - SCOPUS:77949424089

VL - 45

SP - 565

EP - 569

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -